Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation

Louis Williams, Frank Cirrone, Kelli Cole, Maher Abdul-Hay, Leo Luznik, Ahmad Samer Al-Homsi

Research output: Contribution to journalReview articlepeer-review

Abstract

Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Recently, post-transplant cyclophosphamide (PTCy) has emerged as a safe and efficacious alternative. First, omitting the need for ex vivo T-cell depletion in the setting of haploidentical transplantation, growing evidence supports PTCy role in GvHD prevention in matched-related and matched-unrelated transplants. Through improved understanding of GvHD pathophysiology and advancements in drug development, PTCy emerges as a unique opportunity to design calcineurin inhibitor-free strategies by integrating agents that target different stages of GvHD development.

Original languageEnglish (US)
Article number636
JournalFrontiers in immunology
Volume11
DOIs
StatePublished - Apr 9 2020

Keywords

  • GvHD prevention
  • bortezomib
  • calcineurin inhibitor-free
  • matched unrelated donor
  • matched-related donor
  • post-transplant cyclophosphamide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation'. Together they form a unique fingerprint.

Cite this